martes, 21 de junio de 2016

New Information Tools From AHRQ Summarize Treatment Options for Infantile Hemangioma

New Information Tools From AHRQ Summarize Treatment Options for Infantile Hemangioma



New Information Tools From AHRQ Summarize Treatment Options for Infantile Hemangioma

AHRQ Prevention and Chronic Care Program logo

New Information Tools From AHRQ Summarize Treatment Options for Infantile Hemangioma
New evidence-based information tools from AHRQ are available to help clinicians, policymakers, 

parents and caregivers make informed treatment decisions about infantile hemangioma (IH), a 

birthmark caused by abnormal growth of blood vessels. IH is more commonly found in white babies, 

girls, and babies born before 37 weeks of pregnancy.  A research summary and a free continuing 

education module are available for clinicians who treat children with IH.  A brochure for parents 

and caregivers of children with IH supports discussions about the benefits and harms of various 

treatment options including the use of prescription drugs (such as beta-blockers and steroids) and 

surgery. A research summary for policymakers features considerations for possible health care 

programs and policy initiatives. The new tools from AHRQ’s Effective Health Care Program are 

based on a systematic review that evaluated the effectiveness, comparative effectiveness and 

harms of treatment options for patients with infantile hemangioma.

No hay comentarios: